Nomograms Predict Recurrence-free, Overall Survival in Adrenocortical Carcinoma

Share this content:
Researchers developed nomograms that stratified patients with adrenocortical carcinoma into viable prognostic groups.
Researchers developed nomograms that stratified patients with adrenocortical carcinoma into viable prognostic groups.

Researchers developed nomograms that stratified patients with adrenocortical carcinoma (ACC) into viable prognostic groups, according to a study published in JAMA Surgery.1

Prognostic factors for patients with ACC are poorly defined. Investigators sought to propose nomograms for individual risk prediction in patients who had curative surgical resection of ACC.

Investigators used data from 148 patients who underwent surgery for ACC between March 17, 1994 and December 22, 2014, to propose nomograms to predict recurrence-free survival and overall survival.

Median patient age was 53 years and 65.5% were female. Approximately one-third of patients had a functional tumor and median tumor size was 11.2 cm. Ro resection was performed on 77.7% of patients and 8.8% of patients had N1 disease.

Factors that determined RFS prediction included tumor size of at least 12 cm (P < .001), positive nodal status (P = .01), stage 3/4 (P = .07), cortisol-secreting tumor (P = .01), and capsular invasion (P = .04). Factors that were chosen to predict overall survival included tumor size of at least 12 cm (P = .05), positive nodal status (P = .001), and R1 margin (P = .001).

RELATED: IMDC Model Predicts Prognosis for First-line Pazopanib in mRCC

Independent predictors of survival and recurrence risk were used to create the nomograms. The investigators used C statistics, calibration plots, and Kaplan-Meier curves to determine the nomograms' discriminative ability and calibration. Results showed that the nomograms were successful in stratifying patients into prognostic groups.

Reference

  1. Kim Y, Margonis GA, Prescott JD, et al. Nomograms to predict recurrence-free and overall survival after curative resection of adrenocortical carcinoma [published online ahead of print December 16, 2015]. JAMA Surg. doi: 10.1001/jamasurg.2015.4516.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters